Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 2
2016 1
2017 2
2018 2
2019 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for sevuparin
Your search for nevparin retrieved no results
Heparinoid sevuparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins.
Rasmuson J, Kenne E, Wahlgren M, Soehnlein O, Lindbom L. Rasmuson J, et al. FASEB J. 2019 Sep;33(9):10443-10452. doi: 10.1096/fj.201900627R. Epub 2019 Jun 19. FASEB J. 2019. PMID: 31216421
Furthermore, using human neutrophils and endothelial cell monolayers, we demonstrate that sevuparin inhibits hkGAS-induced endothelial barrier disruption by neutralizing the activity of neutrophil-derived proteins. ...-Rasmuson, J., Kenne, E., Wahlgren, M., Soehnlein, O., …
Furthermore, using human neutrophils and endothelial cell monolayers, we demonstrate that sevuparin inhibits hkGAS-induced endothelia …
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, Inati A, Wali Y, Kristensen J, Kowalski J, Donnelly E, Ohd J; TVOC01 Investigators Group. Biemond BJ, et al. Lancet Haematol. 2021 May;8(5):e334-e343. doi: 10.1016/S2352-3026(21)00053-3. Lancet Haematol. 2021. PMID: 33894169 Clinical Trial.
In this study, we tested whether sevuparin could shorten vaso-occlusive crisis duration in hospitalised patients with sickle cell disease. ...There were no deaths in the sevuparin group and there was one (1%) death in the placebo group after a hyper-haemolytic episo …
In this study, we tested whether sevuparin could shorten vaso-occlusive crisis duration in hospitalised patients with sickle cell dis …
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.
Telen MJ, Batchvarova M, Shan S, Bovee-Geurts PH, Zennadi R, Leitgeb A, Brock R, Lindgren M. Telen MJ, et al. Br J Haematol. 2016 Dec;175(5):935-948. doi: 10.1111/bjh.14303. Epub 2016 Aug 23. Br J Haematol. 2016. PMID: 27549988 Free article.
Sevuparin is a novel drug candidate in phase II development as a treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD). ...Importantly, sevuparin prevents vaso-occlusion and normalizes blood flow in an in vivo mouse model of SCD vaso-o …
Sevuparin is a novel drug candidate in phase II development as a treatment for vaso-occlusive crises (VOC) in patients with sickle ce …
Drugs in Development for Malaria.
Ashley EA, Phyo AP. Ashley EA, et al. Drugs. 2018 Jun;78(9):861-879. doi: 10.1007/s40265-018-0911-9. Drugs. 2018. PMID: 29802605 Free PMC article. Review.
Treatment of severe malaria continues to rely on two parenteral drugs with ancient forebears: artesunate and quinine, with sevuparin being evaluated as an adjuvant therapy. Tafenoquine is under review by stringent regulatory authorities for approval as a single-dose treatm …
Treatment of severe malaria continues to rely on two parenteral drugs with ancient forebears: artesunate and quinine, with sevuparin …
Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes.
Saiwaew S, Sritabal J, Piaraksa N, Keayarsa S, Ruengweerayut R, Utaisin C, Sila P, Niramis R, Udomsangpetch R, Charunwatthana P, Pongponratn E, Pukrittayakamee S, Leitgeb AM, Wahlgren M, Lee SJ, Day NP, White NJ, Dondorp AM, Chotivanich K. Saiwaew S, et al. PLoS One. 2017 Mar 1;12(3):e0172718. doi: 10.1371/journal.pone.0172718. eCollection 2017. PLoS One. 2017. PMID: 28249043 Free PMC article.
Sevuparin in concentrations 100 mug/mL inhibited cytoadherence. Sevuparin disrupts P. falciparum rosette formation in a dose dependent manner and inhibits cytoadherence to endothelial cells. The data support assessment of sevuparin as an adjunctive treatment …
Sevuparin in concentrations 100 mug/mL inhibited cytoadherence. Sevuparin disrupts P. falciparum rosette formation in a dose d …
Recent developments in antimalarial drug discovery.
Umumararungu T, Nkuranga JB, Habarurema G, Nyandwi JB, Mukazayire MJ, Mukiza J, Muganga R, Hahirwa I, Mpenda M, Katembezi AN, Olawode EO, Kayitare E, Kayumba PC. Umumararungu T, et al. Bioorg Med Chem. 2023 Jun 6;88-89:117339. doi: 10.1016/j.bmc.2023.117339. Epub 2023 May 20. Bioorg Med Chem. 2023. PMID: 37236020 Review.
Methods to fight malaria are being diversified, including the use of mosquito nets, the target candidate profiles (TCPs) and target product profiles (TPPs) of medicine for malarial venture (MMV) strategy, the search for newer and potent drugs that could reverse chloroquine resist …
Methods to fight malaria are being diversified, including the use of mosquito nets, the target candidate profiles (TCPs) and target product …
Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria.
Leitgeb AM, Charunwatthana P, Rueangveerayut R, Uthaisin C, Silamut K, Chotivanich K, Sila P, Moll K, Lee SJ, Lindgren M, Holmer E, Färnert A, Kiwuwa MS, Kristensen J, Herder C, Tarning J, Wahlgren M, Dondorp AM. Leitgeb AM, et al. PLoS One. 2017 Dec 15;12(12):e0188754. doi: 10.1371/journal.pone.0188754. eCollection 2017. PLoS One. 2017. PMID: 29244851 Free PMC article. Clinical Trial.
To block merozoite invasion has not previously been proposed as an adjunctive therapeutic approach but it may preclude the early expansion of an infection that else leads to exacerbated sequestration and death. SEVUPARIN IN PHASE I STUDY: The drug sevuparin was deve …
To block merozoite invasion has not previously been proposed as an adjunctive therapeutic approach but it may preclude the early expansion o …
Antimalarial compounds in Phase II clinical development.
Held J, Jeyaraj S, Kreidenweiss A. Held J, et al. Expert Opin Investig Drugs. 2015 Mar;24(3):363-82. doi: 10.1517/13543784.2015.1000483. Epub 2015 Jan 7. Expert Opin Investig Drugs. 2015. PMID: 25563531 Review.
12 results